Meta-research on pragmatism of randomized trials: rationale and design of the PragMeta database

被引:3
|
作者
Hirt, Julian [1 ,2 ,3 ,4 ,5 ]
Janiaud, Perrine [1 ,2 ,3 ,4 ]
Dueblin, Pascal [1 ,2 ]
Hemkens, Lars G. [1 ,2 ,3 ,4 ,6 ,7 ]
机构
[1] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Pragmat Evidence Lab, Spital Str 2, CH-4031 Basel, Switzerland
[2] Univ Basel, Spital Str 2, CH-4031 Basel, Switzerland
[3] Univ Hosp Basel, Dept Clin Res, Basel, Switzerland
[4] Univ Basel, Basel, Switzerland
[5] Eastern Switzerland Univ Appl Sci, Inst Nursing Sci, Dept Hlth, St Gallen, Switzerland
[6] Stanford Univ, Meta Res Innova t Ctr Stanford METR, Stanford, CA 94305 USA
[7] Berlin Inst Hlth, Meta Res Innovat Ctr Berlin METRIC B, Berlin, Germany
基金
瑞士国家科学基金会;
关键词
Pragmatic clinical trial [MeSH; Real-world clinical trials; Naturalistic randomized clinical trial; Databases; Bibliographic [MeSH;
D O I
10.1186/s13063-023-07474-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Pragmatic trials provide decision-oriented, real-world evidence that is highly applicable and generalizable. The interest in real-world evidence is fueled by the assumption that effects in the "real-world" are different to effects obtained under artificial, controlled, research conditions as often used for traditional explanatory trials. However, it is unknown which features of pragmatism, generalizability, and applicability would be responsible for such differences. There is a need to provide empirical evidence and promote meta-research to answer these fundamental questions on the pragmatism of randomized trials and real-world evidence. Here, we describe the rationale and design of the PragMeta database which pursues this goal (www.PragMeta.org). Methods PragMeta is a non-commercial, open data platform and infrastructure to facilitate research on pragmatic trials. It collects and shares data from published randomized trials that either have a specific design feature or other characteristic related to pragmatism or they form clusters of trials addressing the same research question but having different aspects of pragmatism. This lays the foundation to determine the relationship of various features of pragmatism, generalizability, and applicability with intervention effects or other trial characteristics. The database contains trial data actively collected for PragMeta but also allows to import and link existing datasets of trials collected for other purposes, forming a large-scale meta-database. PragMeta captures data on (1) trial and design characteristics (e.g., sample size, population, intervention/comparison, outcome, longitudinal structure, blinding), (2) effects estimates, and (3) various determinants of pragmatism (e.g., the use of routinely collected data) and ratings from established tools used to determine pragmatism (e.g., the PRagmatic-Explanatory Continuum Indicator Summary 2; PRECIS-2). PragMeta is continuously provided online, inviting the meta-research community to collaborate, contribute, and/or use the database. As of April 2023, PragMeta contains data from > 700 trials, mostly with assessments on pragmatism. Conclusions PragMeta will inform a better understanding of pragmatism and the generation and interpretation of real-world evidence.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Meta-research on pragmatism of randomized trials: rationale and design of the PragMeta database
    Julian Hirt
    Perrine Janiaud
    Pascal Düblin
    Lars G. Hemkens
    Trials, 24
  • [2] A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols
    Schoenenberger, Christof Manuel
    Griessbach, Alexandra
    Heravi, Ala Taji
    Gryaznov, Dmitry
    Gloy, Viktoria L.
    Lohner, Szimonetta
    Klatte, Katharina
    Ghosh, Nilabh
    Lee, Hopin
    Mansouri, Anita
    Marian, Ioana R.
    Saccilotto, Ramon
    Nury, Edris
    Busse, Jason W.
    von Niederhausern, Belinda
    Mertz, Dominik
    Bluemle, Anette
    Odutayo, Ayodele
    Hopewell, Sally
    Speich, Benjamin
    Briel, Matthias
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 149 : 45 - 52
  • [3] Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects
    Sigurlaug H. Hafliðadóttir
    Carsten B. Juhl
    Sabrina M. Nielsen
    Marius Henriksen
    Ian A. Harris
    Henning Bliddal
    Robin Christensen
    Trials, 22
  • [4] Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects
    Haflidadottir, Sigurlaug H.
    Juhl, Carsten B.
    Nielsen, Sabrina M.
    Henriksen, Marius
    Harris, Ian A.
    Bliddal, Henning
    Christensen, Robin
    TRIALS, 2021, 22 (01)
  • [5] Incomplete reporting of adverse events in duloxetine trials: a meta-research survey of randomized controlled trials vs placebo
    Rolland, P.
    Jutel, A.
    Douget, K.
    Naudet, F.
    Roy, J. C.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2025, 180
  • [6] Methods Used for Enhancing the Bioavailability of Oral Curcumin in Randomized Controlled Trials: A Meta-Research Study
    Mimica, Bruna
    Popovic, Viljemka Bucevic
    Banjari, Ines
    Kadic, Antonia Jelicic
    Puljak, Livia
    PHARMACEUTICALS, 2022, 15 (08)
  • [7] A Critical Appraisal of Reporting in Randomized Controlled Trials Investigating Osteopathic Manipulative Treatment: A Meta-Research Study
    Mazzoleni, Gabriele Zambonin
    Bergna, Andrea
    Buffone, Francesca
    Sacchi, Andrea
    Misseroni, Serena
    Tramontano, Marco
    Dal Farra, Fulvio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (17)
  • [8] Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources
    Riechelmann, Rachel P.
    Peron, Julien
    Seruga, Rostjan
    Saad, Everardo D.
    ONCOLOGIST, 2018, 23 (12): : 1467 - 1473
  • [9] A review identified challenges distinguishing primary reports of randomized trials for meta-research: A proposal for improved reporting
    Nicholls, Stuart G.
    McDonald, Steve
    McKenzie, Joanne E.
    Carroll, Kelly
    Taljaard, Monica
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 145 : 121 - 125
  • [10] CONSORT statement adherence and risk of bias in randomized controlled trials on deep caries management: a meta-research
    Elagami, Rokaia Ahmed
    Reis, Thais Marchezini
    Hassan, Mohamed Ahmed
    Tedesco, Tamara Kerber
    Braga, Mariana Minatel
    Mendes, Fausto Medeiros
    Cenci, Maximiliano Sergio
    Huysmans, Marie-Charlotte
    Raggio, Daniela Procida
    BMC ORAL HEALTH, 2024, 24 (01):